Early right-heart stabilization seems to be translating to better QoL and faster return of function, says Robert Lookstein.

The study questions whether it may be best to wait to implant a support device until arriving at a level 1 shock center.

Lauren Eberly, Stephen Paul Juraschek, and Oluwabunmi Ogungbe discuss what they learned as researchers exploring novel ...

This month: dental costs and increased CVD risk, targeting fear of movement, workplace wellness programs, and more.

The absolute rate is still below 0.5%, in line with prior ablation studies, but the issue warrants monitoring, a researcher ...

In line with earlier studies of the general population, the findings should encourage a thoughtful approach to calcium, ...

At 30 days, bleeding and pacemaker rates were lower than in TRISCEND II, but long-term outcomes are eagerly awaited.

Yet the evidence should not be overinterpreted, as conventional pacing maintains an important role, says Elena Arbelo.

NEW ORLEANS, LA—Adding the factor XIa inhibitor asundexian (Bayer) to antiplatelet therapy tops antiplatelet therapy alone ...

The addition of stenting to usual care reduced symptoms and improved quality of life for patients with the condition after ...

Known for his skills as a clinician and educator, Montorfano contributed much to the interventional cardiology community.

The IMPACTS-BP trial showed that SPRINT-like reductions in systolic BP are possible even in tough real-world scenarios.